Company Filing History:
Years Active: 2024-2025
Title: Mikhail H. Hanewich-Hollatz: Innovator in CRISPR Technology
Introduction
Mikhail H. Hanewich-Hollatz is a distinguished inventor based in Pasadena, California, known for his significant contributions to the field of genetic engineering. With a total of two patents to his name, he plays a crucial role in the CRISPR revolution that is transforming biology and medicine.
Latest Patents
His latest patent focuses on "Allosteric Conditional Guide RNAs for Cell-Selective Regulation of CRISPR/Cas." This innovation showcases programmable guide RNAs (gRNAs) that are central to directing the function of a Cas protein effector to a target gene. The conditional guide RNA (cgRNA) mechanism depends on the presence or absence of an RNA trigger, allowing for precise, cell-selective regulation of CRISPR/Cas functions. The design of cgRNAs enables independent tailoring of both target-binding and trigger-binding sequences, offering remarkable flexibility in selecting regulatory targets and scopes. Additionally, the patent outlines allosteric cgRNA mechanisms facilitating both ON→OFF and OFF→ON logic for conditional activation or inactivation by an RNA trigger. This groundbreaking technology has potential applications as a versatile platform for research tools, diagnostics, and therapeutics tailored to specific cell types and disease states.
Career Highlights
Mikhail H. Hanewich-Hollatz is affiliated with the California Institute of Technology, a leading institution known for its cutting-edge research and innovation. His work embodies the intersection of advanced technology and biology, contributing to the leap forward in genomic editing capabilities.
Collaborations
Throughout his career, Mikhail has collaborated with notable colleagues, including Lisa Hochrein and Zhewei Chen. These partnerships have undoubtedly enriched his research endeavors and enhanced the potential impacts of his innovations.
Conclusion
Mikhail H. Hanewich-Hollatz stands out as a promising inventor whose work in CRISPR technology holds the potential to transform therapeutic approaches in medicine. With his innovative patents and collaborative spirit, he is poised to make lasting contributions to the fields of genetics and biotechnology.